Kither Biotech is a biopharma company focused on the development of new drug candidates for the treatment of rare pulmonary diseases, with primary focus on cystic fibrosis

In 2022, completed €18.5mln Series B round to fund the clinical development of lead asset KIT2014In 2019, completed €5.6mln Series A round in mid-2019 to fund the preclinical development of lead asset for the treatment of Cystic Fibrosis KIT2014 as an add-on therapy for current standard of care for Cystic Fibrosis

Leading Italian company in consumer finance sector (AUM: €15bln), evaluating expansion opportunities in India and South East AsiaCompleted conditional purchase of minority stake of listed consumer finance company in Indonesia

Holding company of integrated retail credit institutions focusing on artisans and micro-enterprises in India and South East AsiaThe Group was active with majority-owned microfinance companies in India, Indonesia and the Philippines, with over 1.8 million clients and employing 7,500 peopleThe shareholder base counted 100+ HNWI investors and some institutional investors

Venture capital unit of single-family office active in impact investing with $120mln fund. DOB invests in innovative start-ups and SMEs in East Africa

Wealth management start-up firm, active in private banking and fund managementJoined a year after the launch to lead operations following departure of founding CEO, until its successful sale to new shareholders

Private investment vehicle, raising capital from HNW individuals on a deal-by-deal basisOperated as investor and interim executive to lead execution of business plan post-investmentLed completion of eight investments, between $300k–$5.0 mln

Private equity firm evaluating investments in Europe. At the time, CVC managed a $3.1bln fundCompleted three acquisitions (values $70mln-$300mln)

Chemicals group with sales of $1.5bln and operations in seven countries in Europe. Listed on the Amsterdam Stock Exchange